Literature DB >> 12029150

Transient immune suppression of inapparent carriers infected with a principal neutralizing domain-deficient equine infectious anaemia virus induces neutralizing antibodies and lowers steady-state virus replication.

Jodi K Craigo1, Caroline Leroux1, Laryssa Howe1, Jonathan D Steckbeck1, Sheila J Cook2, Charles J Issel2, Ronald C Montelaro1.   

Abstract

The genetic variation of equine infectious anaemia virus (EIAV) clearly affects the antigenic properties of the viral envelope; however, effects on immunogenicity remain undefined, although widely assumed. Here, the immunogenicity is reported of a novel, neutralization-resistant, pony-isolate envelope EIAV(PV564DeltaPND) that contains a 14-residue deletion in the designated principal neutralizing domain (PND) of the gp90 protein. Two ponies inoculated with a chimeric virus, EIAV(DeltaPND), containing the EIAV(PV564DeltaPND) envelope in a reference provirus strain, remained asymptomatic through 14 months post-inoculation, producing high steady-state levels of envelope-specific antibodies but no detectable serum-neutralizing antibodies. Consequent dexamethasone-induced immune suppression produced characteristic EIA that resolved concomitantly with the development of high-titre, strain-specific, neutralizing antibodies and a 100-fold reduction in steady-state virus loads. These results demonstrate: natural variations in the EIAV envelope have profound effects on both antigenic and immunogenic properties; the PND is not required for neutralizing antibody responses; and transient immune suppression can enhance established host immunity to achieve more effective control of steady-state lentivirus replication.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12029150     DOI: 10.1099/0022-1317-83-6-1353

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  17 in total

1.  Envelope variation as a primary determinant of lentiviral vaccine efficacy.

Authors:  Jodi K Craigo; Baoshan Zhang; Shannon Barnes; Tara L Tagmyer; Sheila J Cook; Charles J Issel; Ronald C Montelaro
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-10       Impact factor: 11.205

2.  Immune suppression of challenged vaccinates as a rigorous assessment of sterile protection by lentiviral vaccines.

Authors:  Jodi K Craigo; Shannon Durkin; Timothy J Sturgeon; Tara Tagmyer; Sheila J Cook; Charles J Issel; Ronald C Montelaro
Journal:  Vaccine       Date:  2006-09-22       Impact factor: 3.641

3.  Selection of a rare neutralization-resistant variant following passive transfer of convalescent immune plasma in equine infectious anemia virus-challenged SCID horses.

Authors:  Sandra D Taylor; Steven R Leib; Susan Carpenter; Robert H Mealey
Journal:  J Virol       Date:  2010-04-14       Impact factor: 5.103

4.  Development of a high throughput, semi-automated, infectious center cell-based ELISA for equine infectious anemia virus.

Authors:  Jodi K Craigo; Corin Ezzelarab; Ronald C Montelaro
Journal:  J Virol Methods       Date:  2012-07-20       Impact factor: 2.014

5.  Unique evolution characteristics of the envelope protein of EIAV(LN₄₀), a virulent strain of equine infectious anemia virus.

Authors:  Xuefeng Wang; Shuai Wang; Yuezhi Lin; Chenggang Jiang; Jian Ma; Liping Zhao; Xiaoling Lv; Fenglong Wang; Rongxian Shen; Jianhua Zhou
Journal:  Virus Genes       Date:  2011-01-08       Impact factor: 2.332

6.  Discerning an effective balance between equine infectious anemia virus attenuation and vaccine efficacy.

Authors:  Jodi K Craigo; Feng Li; Jonathan D Steckbeck; Shannon Durkin; Laryssa Howe; Sheila J Cook; Charles Issel; Ronald C Montelaro
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

7.  Amino acid mutations in the env gp90 protein that modify N-linked glycosylation of the Chinese EIAV vaccine strain enhance resistance to neutralizing antibodies.

Authors:  Xiue Han; Ping Zhang; Wei Yu; Wenhua Xiang; Xiaodong Li
Journal:  Virus Genes       Date:  2016-08-29       Impact factor: 2.332

8.  Epitope shifting of gp90-specific cellular immune responses in EIAV-infected ponies.

Authors:  Chong Liu; Sheila J Cook; Jodi K Craigo; Frank R Cook; Charles J Issel; Ronald C Montelaro; David W Horohov
Journal:  Vet Immunol Immunopathol       Date:  2014-08-10       Impact factor: 2.046

9.  Equine infectious anemia virus envelope evolution in vivo during persistent infection progressively increases resistance to in vitro serum antibody neutralization as a dominant phenotype.

Authors:  Laryssa Howe; Caroline Leroux; Charles J Issel; Ronald C Montelaro
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

10.  An EIAV field isolate reveals much higher levels of subtype variability than currently reported for the equine lentivirus family.

Authors:  Jodi K Craigo; Shannon Barnes; Baoshan Zhang; Sheila J Cook; Laryssa Howe; Charles J Issel; Ronald C Montelaro
Journal:  Retrovirology       Date:  2009-10-20       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.